\n\n\n\n\t\t\n\t\t\tOthera Pharmaceuticals\n\t\t\thttp://www.othera.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tOthera Pharmaceuticals, Inc. is a privately-held specialty pharmaceuticals company focused on the design and development of small molecule products for ophthalmology, oncology, and inflammatory...More»
\n\t\t\tOthera Pharmaceuticals, Inc. is a privately-held specialty pharmaceuticals company focused on the design and development of small molecule products for ophthalmology, oncology, and inflammatory diseases.
Othera\u2019s ophthalmic product candidates address large unmet medical needs that are expected to grow rapidly as the generation of baby boomers age. Othera is driving innovation with the development of an eye drop treatment for the dry form of AMD, which affects over 12 million Americans. Currently, no FDA-approved pharmaceutical treatment exists for dry AMD, which affects 85-90% of all people who suffer from AMD. According to the National Institutes of Health, the number of Americans suffering from AMD and glaucoma is expected to double over the next 10 years.«Less
Overview
\n\t\t\t\tLocation: \tExton, PA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\tpharmaceutical,\n\t\t\t\tothera,\n\t\t\t\tbiotech,\n\t\t\t\tmedical,\n\t\t\t\tdrug,\n\t\t\t\tHealthcare\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Seed - $0.075M (07/2007)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tTEDCO\n\t\t\t\t
\n\t\t\tMarket
\n\n\t\t\t\tRelated Companies:\n\t\t\t\t\tTragara Pharmaceuticals,\n\t\t\t\t\tOcera Therapeutics,\n\t\t\t\t\tGenelabs Technologies,\n\t\t\t\t\tAltea Therapeutics,\n\t\t\t\t\tIO Informatics,\n\t\t\t\t\tMedAvante,\n\t\t\t\t\tCadence Pharmaceuticals,\n\t\t\t\t\tEsperion Therapeutics,\n\t\t\t\t\tPOINT Biomedical,\n\t\t\t\t\tCelator Pharmaceuticals\n\t\t\t\t
\n\t\t\t